In lung cancer, miR-138-5p inhibition could promote carcinogenesis and progression by targeting E2F3, CDK8, ZEB2, PD-L1, and PD-1 [32–35], and the present results displayed that miR-138-5p is downregulated in LUSC tissues and cells. Here, E2F3 is linked to lung cancer.